Study objective

Review highlights

Pregnancy planning and MS

EMA and FDA recommendations for DMT use in women with MS

 Oral DMTs

  • All are contraindicated during pregnancy
  • Contraindicated during breastfeeding: Teriflunomide and cladribine
  • Consider benefits against possible risks during breastfeeding: Dimethyl fumarate, fingolimod, and siponimod

Oral DMTs

  • All are contraindicated during pregnancy
  • Contraindicated during breastfeeding: Teriflunomide and cladribine
  • Consider benefits against possible risks during breastfeeding: Dimethyl fumarate, fingolimod, and siponimod

 Injectable monoclonal antibodies

  • Continue till conception or until 2nd trimester: Natalizumab
  • Consider benefits of breastfeeding against possible risks for all
  • Contraindicated during pregnancy: Alemtuzumab, and ocrelizumab

Key considerations

Support and encourage women with MS for pregnancy and exclusive breastfeeding

Family planning strategies for MS patients have changed

Individualize therapy for any pregnant woman

Consider the chances of conception in relation to DMTs without any risk to the fetus and safety during the postpartum period

ARR: Annualized relapse rate; DMTs: Disease-modifying therapies; EMA: European Medicines Agency; FDA: Food and Drug Administration; MS: Multiple sclerosis; US: United States.this study has not been reviewed by SFDA

    Simone IL, Tortorella C, Ghirelli A. Influence of pregnancy in multiple sclerosis and impact of disease-modifying therapies. Front Neurol. 2021;12:697974.

Aubagio API

MAT-BH-2300590-V1-Oct.2023